Key Takeaways
- ARS Pharmaceuticals ($SPRY) reported first-quarter 2026 revenue of $28.5 million, significantly exceeding analyst estimates of $22.0 million.
- Shares of ARS Pharmaceuticals ($SPRY) surged 28.7% to $15.80 in post-market trading following the release.
- The company raised its full-year 2026 revenue guidance to a range of $120 million to $130 million, signaling robust *neffy* adoption.
- Operational updates highlighted strong physician and patient uptake for *neffy*, alongside secure manufacturing supply chains.
- Management indicated progress on international expansion plans and a pediatric indication for *neffy*, with a PDUFA date anticipated in Q3 2026.
Strong neffy Launch Drives Record Revenue Growth
ARS Pharmaceuticals, Inc. ($SPRY) reported first-quarter 2026 revenue of $28.5 million, significantly surpassing the consensus analyst estimate of $22.0 million and marking a substantial increase from Q4 2025 sales of $15.2 million. The company also announced a narrower net loss of $0.12 per share, outperforming expectations for a $0.18 per share loss.
The robust top-line performance, primarily attributed to accelerating adoption of its neffy epinephrine nasal spray in the U.S. market, prompted an immediate positive market reaction. $SPRY shares climbed sharply in extended trading, reflecting investor confidence in the commercial execution of its flagship product.
During the earnings call, management elaborated on the successful commercialization strategy for neffy, citing strong physician prescribing patterns and high patient refill rates. The company highlighted that over 7,000 unique prescribers have initiated neffy prescriptions since its launch, with a 65% refill rate observed among patients after their initial 30-day supply. This indicates sustained demand and positive patient experience with the novel treatment.
Furthermore, ARS Pharmaceuticals raised its full-year 2026 revenue guidance to a range of $120 million to $130 million, up from previous projections of $95 million to $105 million. This upward revision underscores management's optimism regarding neffy's continued market penetration and its potential to capture a significant share of the epinephrine market. The company also confirmed a healthy cash position of $250 million as of March 31, 2026, providing substantial liquidity for ongoing commercial and development activities.
Market Impact
$SPRY shares soared 28.7% to close at $15.80 in after-hours trading on Tuesday, adding approximately $190 million to its market capitalization, which now stands at $850 million. The trading volume spiked to over 6.5 million shares, five times its 30-day average, signaling strong institutional and retail investor interest. This represents the largest single-day percentage gain for ARS Pharmaceuticals since its FDA approval for neffy in July 2025.
The significant price movement pushed $SPRY above its 200-day moving average of $13.10 for the first time in three months, potentially establishing a new technical support level. The stock had traded in a range between $10.50 and $14.00 for most of Q1 2026, making this breakout a notable technical event for chart watchers.
The strong performance in the biopharmaceutical sector, particularly for companies with recently launched innovative therapies, could signal broader investor confidence in novel drug delivery systems. While not directly impacting large-cap pharmaceutical companies, the positive sentiment may extend to other small-to-mid-cap biotech firms awaiting product launches or regulatory milestones, potentially attracting capital flows into the broader specialty pharma segment. Cross-asset implications are limited, though broader healthcare sector ETFs like $XLV could see marginal uplift from improved investor sentiment toward emerging biotechs.
What Analysts Are Saying
Oppenheimer analysts reiterated their "Outperform" rating on $SPRY, raising their price target from $18.00 to $22.00 per share following the earnings release. "The neffy launch trajectory is exceeding even our most optimistic projections, demonstrating strong physician uptake and patient adherence," stated Oppenheimer's biotech research team in a client note dated May 13, 2026. "The updated full-year guidance of $120-$130 million provides a clear path to profitability by mid-2027, driven by efficient commercialization and expanding market access."
Conversely, Leerink Partners maintained a "Market Perform" rating, acknowledging the strong initial sales but highlighting potential future competition and reimbursement hurdles. "While Q1 2026 revenue was impressive, we remain cautious regarding the long-term competitive landscape, particularly from existing injectable epinephrine products and other nasal spray candidates in development," wrote a Leerink analyst. "Reimbursement dynamics across various payors will be crucial for sustained growth beyond initial stocking, and these challenges could cap upside despite strong early adoption."
Cantor Fitzgerald upgraded $SPRY from "Neutral" to "Overweight," citing the company's robust cash position of $250 million as of March 31, 2026, which provides ample runway for continued commercialization efforts and pipeline development without immediate dilution concerns. "The financial stability allows ARS to aggressively pursue market share and invest in further label expansion, including the pediatric indication and potential international markets, bolstering its long-term growth profile," their report noted.
What to Watch
Investors will closely monitor $SPRY's Q2 2026 earnings call, anticipated in early August 2026, for further updates on neffy's commercial performance, particularly refill rates and new physician prescribing trends. Any deviation from the revised full-year revenue guidance of $120 million to $130 million could trigger significant volatility in the stock.
A key upcoming catalyst includes the anticipated PDUFA (Prescription Drug User Fee Act) date for neffy's pediatric indication, which management expects in Q3 2026. A positive decision from the FDA would significantly expand the addressable market for neffy and could provide another substantial boost to the stock price.
Technically, the $15.00 level will serve as immediate support for $SPRY shares, with resistance potentially forming around the $18.00 mark, a price level last seen in late 2025. A sustained break above $18.00 could open the path towards Oppenheimer's revised price target of $22.00, while a drop below $15.00 might retest the previous resistance around $14.00.
Risk factors that could reverse the current positive momentum include potential delays in international market approvals, unexpected competition from generic or alternative epinephrine delivery systems, and any adverse changes in the reimbursement landscape that could impact neffy's accessibility and pricing. Updates on competitor EpiPen sales from Viatris ($VTRS) will also be relevant for ongoing market share analysis.
